Cai Jiaqin, Wei Xiaoxia, Zhang Guifeng, Sui Yuxia, Zhuang Jie, Liu Zhenhua, Sun Hong
Department of Pharmacy.
Department of Oncology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, Fujian, PR China.
Medicine (Baltimore). 2019 Feb;98(6):e14168. doi: 10.1097/MD.0000000000014168.
SUMO-specific Cysteine Proteases (SENPs) have involvement in the initiation and progression of human cancers. In the present study, we evaluated the association of SENPs polymorphism with susceptibility as well as clinicopathologic features and patients' response of breast cancer (BC) in a Chinese population.We genotyped SENP1 (rs61918808), SENP2 (rs6762208), SENP7 (rs61697963) by sequencing in a case-control study including 210 BC patients and 225 healthy volunteers. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assume the association strength.No significant association was found between polymorphism of the 3 SENPs and BC susceptibility. However, SENP1 rs61918808 (C>T) and SENP7 rs61697963 (A>C) was associated with HER-2 expression (P < .05). SENP2 rs6762208(C>A) was correlated with increasing risk of lymph node metastases (P < .05). Among the patients who received neoadjuvant chemotherapy, T allele and TT genotype of SENP1 rs61918808 were less likely to achieve pCR (P < .05).We first reported SENPs variants were not associated with BC risk in Chinese population, but presented specific effect on clinicopathological features of BC. Moreover, SENP1 rs61918808 may be a predictor for the clinical response in local advanced BC patients who received neoadjuvant chemotherapy.
小泛素样修饰特异性半胱氨酸蛋白酶(SENPs)与人类癌症的发生和发展有关。在本研究中,我们评估了SENPs基因多态性与中国人群乳腺癌(BC)易感性、临床病理特征及患者反应之间的关联。在一项包含210例BC患者和225名健康志愿者的病例对照研究中,我们通过测序对SENP1(rs61918808)、SENP2(rs6762208)、SENP7(rs61697963)进行基因分型。采用比值比(OR)和95%置信区间(CI)来评估关联强度。未发现这3种SENPs的基因多态性与BC易感性之间存在显著关联。然而,SENP1 rs61918808(C>T)和SENP7 rs61697963(A>C)与HER-2表达相关(P<0.05)。SENP2 rs6762208(C>A)与淋巴结转移风险增加相关(P<0.05)。在接受新辅助化疗的患者中,SENP1 rs61918808的T等位基因和TT基因型不太可能达到病理完全缓解(pCR)(P<0.05)。我们首次报道,在中国人群中SENPs变异与BC风险无关,但对BC的临床病理特征有特定影响。此外,SENP1 rs61918808可能是接受新辅助化疗的局部晚期BC患者临床反应的一个预测指标。